Home
Clinical Resources Search
PQI: Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

Last Updated: May 28, 2024

By: Latha Radhakrishnan, PharmD, BCPS, BCOP

About this PQI

The granisetron transdermal system is a 5-HT3 Receptor Antagonist (5-HT3 RA) that allows for an alternate medication delivery compared to oral or parenteral administration. The purpose of this PQI is to review appropriate patient identification and discuss clinical considerations for the use of granisetron in chemotherapy induced nausea and vomiting (CINV).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video CINV Nausea & Vomiting (N/V) Supportive Care

PQI

PQI in Action: Nirogacestat (Ogsiveo) use in Management of Adults with Progressing Desmoid Tumors (or fibromatosis or aggressive fibromatosis)

Last Updated: 10/04/2025

PQI in Action

PQI in Action: Abiraterone acetate (Yonsa) Patient Selection and Management

Last Updated: 09/10/2025

PQI in Action

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

Last Updated: 09/10/2025

PQI Podcast

Frequently Searched

Supported by

Granisetron Transdermal System (Sancuso®) for Chemotherapy Induced Nausea and Vomiting

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

PQI: Datopotamab deruxtecan (DATROWAY): Prophylaxis and Management of Adverse Events

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI in Action: Nirogacestat (Ogsiveo) use in Management of Adults with Progressing Desmoid Tumors (or fibromatosis or aggressive fibromatosis)

PQI in Action: Abiraterone acetate (Yonsa) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

S9 E9: The Realities of Ethics in Oncology

S9 E8: Mental Strength at Work

S9 E7: A Haven of Healing

S9 E6: Healing Through Sound: A Breast Cancer Journey

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Understanding Nausea and Vomiting During Cancer Treatment

PQI: Sacituzumab govitecan-hziy (Trodelvy®): Prophylaxis and Management of Adverse Events

PQI: Chemotherapy-Induced Nausea and Vomiting

PQI: Netupitant/Fosnetupitant and Palonosetron (Akynzeo®) for Chemotherapy-Induced Nausea and Vomiting

PQI: Olanzapine (Zyprexa®) In Chemotherapy Induced Nausea and Vomiting

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

How to Categorize Cancer Drug Therapy

PQI: Bone Health and the Cancer Patient

The PQI Podcast S4 Ep 5: Role of Oncology Social Worker

Daratumumab and KRd

Daratumumab and VRd

Taletrectinib

PQI: Datopotamab deruxtecan (DATROWAY): Prophylaxis and Management of Adverse Events